PHILADELPHIA - Stand Up To Cancer (SU2C) and the Melanoma Research Alliance (MRA), along with the American Association for Cancer Research, call upon the cancer research community to submit Letters of Intent for a new Dream Team dedicated to melanoma research.
The SU2C-MRA Melanoma Dream Team Translational Cancer Research Grant will provide funding of a minimum of $6 million over a three-year period for a cancer research project that will accelerate the application of new preventive, diagnostic or therapeutic agents to the clinic. Proposals for Melanoma Dream Team projects must present plans indicating how the work will be translated into the clinic.
To maximize creativity, innovation and collaboration, the Dream Team must include laboratory and clinical researchers, senior and young investigators and senior scientists who have not worked together in the past, as well as patient advocates. This Dream Team will span multiple disciplines and utilize the new tools of modern biology to attack research questions in a coordinated way. Mechanisms to foster collaboration within and among the Dream Teams should be employed - an approach that promotes the sharing of information and a goal-oriented focus on measurable milestones of progress.
SU2C and MRA believe that this unique Dream Team model will advance scientific research in the interests of both todays cancer patients and those who may develop cancer in the future.
A SU2C-MRA Joint Scientific Advisory Committee (JSAC) will conduct a unique, interactive, rapid and rigorous evaluation of the applications via a multi-step scientific review process. The committee is chaired by Nobel Laureate Phillip A. Sharp, Ph.D., Institute Professor, David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, and is comprised of highly accomplished senior laboratory researchers and physician-scientists, as well as advocates.
Since the launch of Stand Up To Cancer in 2008, the AACR has played an integral role as SU2Cs scientific partner by providing scientific leadership, expert peer review and grants administration. The AACR is responsible for administering these grants and provides ongoing scientific oversight to ensure that progress is being made. AACR will work closely with MRA, the largest private funder of melanoma research.
For general information on eligibility criteria, the application process and other details about this Dream Team grant, please visit: www.aacr.org/SU2CMRA . Inquiries may be directed to the SU2C Grants Office at: (267) 765-1049 or firstname.lastname@example.org . Those interested should submit Letters of Intent detailing their best ideas for cutting-edge melanoma research projects to email@example.com  by 12:00 p.m. (noon) ET on June 20, 2011.
The SU2C-MRA Melanoma Translational Dream Team will be announced in November 2011.
# # #
About Stand Up To Cancer
About the Entertainment Industry Foundation
About the Melanoma Research Alliance
About the American Association for Cancer Research